 Neoadjuvant chemotherapy nonmetastatic osteosarcoma extremities Between September December patients osteosarcoma extremities second neoadjuvant study authors institution Patients cycles methotrexate MTX cisplatinum CDP adriamycin ADM surgery patients good responders tumor necrosis ADM MTX CDP poor responders tumor necrosis chemotherapy ifosfamide etoposide addition MTX ADM CDP Limb salvage possible patients amputation rotationplasty surgical margins adequate radical wide cases inadequate marginal intralesional average follow-up period months range patients disease free pulmonary metastases patient local recurrence first neoadjuvant study authors institution MTX CDP percentage limb salvages good responders disease-free survival years second Rizzoli neoadjuvant study Systemic toxicity chemotherapy superimposable retrospective analysis real dose intensity patient correlation intensity chemotherapy prognosis